MX2022006523A - Composicion que comprende budesonida para uso oftalmico. - Google Patents
Composicion que comprende budesonida para uso oftalmico.Info
- Publication number
- MX2022006523A MX2022006523A MX2022006523A MX2022006523A MX2022006523A MX 2022006523 A MX2022006523 A MX 2022006523A MX 2022006523 A MX2022006523 A MX 2022006523A MX 2022006523 A MX2022006523 A MX 2022006523A MX 2022006523 A MX2022006523 A MX 2022006523A
- Authority
- MX
- Mexico
- Prior art keywords
- budesonide
- composition
- ophthalmic use
- inflammation
- mixtures
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 title abstract 3
- 229960004436 budesonide Drugs 0.000 title abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 238000009109 curative therapy Methods 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 210000005252 bulbus oculi Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000375 suspending agent Substances 0.000 abstract 1
- 239000002562 thickening agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a budesonida, o una sal de la misma, o mezclas de la misma para uso oftálmico en un procedimiento para el tratamiento curativo de un trastorno o una dolencia ocular o una enfermedad en un sujeto que lo necesita. Además, la presente invención se refiere a una composición que comprende una mezcla que comprende o, alternativamente, que consiste en: (i) una budesonida, o una sal de la misma, o mezclas de la misma; (ii) al menos un agente de suspensión/espesante, y opcionalmente uno o más excipientes fisiológica y/o farmacológicamente aceptables; siendo dicha composición para su uso en un procedimiento para el tratamiento curativo de una inflamación de los anexos oculares o una inflamación del globo ocular en un sujeto que lo necesite.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102019000022860A IT201900022860A1 (it) | 2019-12-03 | 2019-12-03 | Composizione comprendente budesonide per uso oftalmico |
| IT102019000022881A IT201900022881A1 (it) | 2019-12-03 | 2019-12-03 | Budesonide per uso oftalmico in un metodo di trattamento dell’occhio |
| PCT/IB2020/061444 WO2021111358A1 (en) | 2019-12-03 | 2020-12-03 | Composition comprising budesonide for ophthalmic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006523A true MX2022006523A (es) | 2022-07-01 |
Family
ID=74004126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006523A MX2022006523A (es) | 2019-12-03 | 2020-12-03 | Composicion que comprende budesonida para uso oftalmico. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220409633A1 (es) |
| EP (1) | EP4069249A1 (es) |
| CN (1) | CN114746098A (es) |
| AU (1) | AU2020394893A1 (es) |
| CA (1) | CA3163198A1 (es) |
| IL (1) | IL293376A (es) |
| MX (1) | MX2022006523A (es) |
| WO (1) | WO2021111358A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102640948B1 (ko) * | 2021-11-22 | 2024-02-23 | 가톨릭대학교 산학협력단 | 3d 프린터를 이용한 맞춤형 페서리의 제조 시스템, 제조 방법 및 이에 의해 제조되는 환자 맞춤형 페서리 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070020299A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
| CN101987101A (zh) * | 2009-08-05 | 2011-03-23 | 天津金耀集团有限公司 | 糖皮质激素芳香基氨磺酰基磺酸酯为活性成分的眼用抗炎组合物 |
| RU2585003C2 (ru) * | 2014-06-09 | 2016-05-27 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ введения добавок в полимеры |
| AU2017261303B9 (en) * | 2016-05-06 | 2021-09-23 | Sacsh, Inc. | Ophthalmic compositions |
-
2020
- 2020-12-03 WO PCT/IB2020/061444 patent/WO2021111358A1/en unknown
- 2020-12-03 EP EP20829208.6A patent/EP4069249A1/en active Pending
- 2020-12-03 US US17/777,964 patent/US20220409633A1/en active Pending
- 2020-12-03 AU AU2020394893A patent/AU2020394893A1/en not_active Abandoned
- 2020-12-03 IL IL293376A patent/IL293376A/en unknown
- 2020-12-03 CN CN202080083485.9A patent/CN114746098A/zh active Pending
- 2020-12-03 CA CA3163198A patent/CA3163198A1/en active Pending
- 2020-12-03 MX MX2022006523A patent/MX2022006523A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020394893A1 (en) | 2022-06-23 |
| IL293376A (en) | 2022-07-01 |
| EP4069249A1 (en) | 2022-10-12 |
| CN114746098A (zh) | 2022-07-12 |
| US20220409633A1 (en) | 2022-12-29 |
| CA3163198A1 (en) | 2022-06-10 |
| WO2021111358A1 (en) | 2021-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017158366A3 (en) | Ophthalmic delivery device and ophthalmic drug compositions | |
| MX2010003774A (es) | Formulaciones oftalmicas acuosas. | |
| MX2019013799A (es) | Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo. | |
| WO2019195761A3 (en) | Pharmacological agents for treating ocular diseases | |
| MX2020006309A (es) | Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis. | |
| EA202191684A1 (ru) | Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии | |
| MY178169A (en) | Topical ophthalmic peptide formulation | |
| WO2013184650A3 (en) | Treatment of ocular inflammatory diseases using laquinimod | |
| MX2020007948A (es) | Medicamento para prevenir o tratar una enfermedad oftalmica asociada con neovascularizacion intraocular mejorada y/o permeabilidad vascular intraocular. | |
| MX2018001918A (es) | Aplicación cuantitativa periorbital de farmacos oftalmologicos. | |
| MX2022006523A (es) | Composicion que comprende budesonida para uso oftalmico. | |
| JP2015523986A5 (es) | ||
| MX2021005077A (es) | Peptidos y composiciones farmaceuticas para tratar enfermedades oculares. | |
| MX2021015338A (es) | Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. | |
| MX2020011536A (es) | Deposito de liquido para liberacion sostenida no invasiva de agentes al ojo. | |
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
| WO2018234871A3 (en) | COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| EA202192183A1 (ru) | Композиции, обладающие активностью удаления липофусцина из клеток сетчатки | |
| WO2021050692A3 (en) | Methods for alleviating pterygium-associated worry about eye appearance | |
| MX2020011535A (es) | Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina. | |
| MX2022000297A (es) | Formulacion de naltrexona. | |
| PH12020500001A1 (en) | Non-pulsatile prolonged-release betahistine oral solid compositions | |
| MX2021015796A (es) | Composiciones y metodos para tratar enfermedades oculares. | |
| HK1252301A2 (zh) | 一種含有重組人溶菌酶的新型人工淚液 |